I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

ELCC 2019

European Lung Cancer Congress 2019

As a diverse meeting of multidisciplinary experts, the annual ELCC provides a collaborative forum for discussing advances in clinical research and communicating practice-changing data in thoracic oncology.

 

At the congress, Boehringer Ingelheim will be hosting a symposium and recent findings related to our compounds will be presented. Please see below for more information, and revisit this page for further details nearer the event.

Symposium: Sequencing algorithms in NSCLC
symposium_cal
11 April 2019
symposium_cal
18:00pm - 19:00pm
symposium_cal
Room A

Join us at our ELCC symposium to hear a faculty of renowned experts discuss the sequence of treatment in EGFR-mutation positive NSCLC and in non-mutated, non-squamous advanced NSCLC, and pose your questions on these topics.

 

For more details, click here to download the invitation flyer. 

        Vanesa Gregorc

Vanesa Gregorc

IRCCS San Raffaele Hospital, Milan

Chair; Moderator of  Q&A  sessions

        Nicolas Girard

Nicolas Girard

Thorax Institute Curie-Montsouris

Prolonging the chemotherapy-free period in EGFR-mutation positive NSCLC

        Martin Reck

Martin Reck

Lung Clinic Grosshansdorf

Recent changes and sequencing strategies in non-mutated, non-squamous advanced NSCLC

Publications
Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumour Type
  • All tumour types

Come and find out more about our emerging data and the investigator-initiated VARGADO study during the scientific programme at ELCC.

Thursday 11th April 2019
Afatinib* in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: an interim analysis of a Phase IIIB trial
Thursday 11th April 2019
08:00-08:50
Room A
Presenter(s): Passaro et al.
Oral Presentation
Tumour Type(s): NSCLC
Presentation Number: 115O
Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
Thursday 11th April
16:40-17:40
Room C
Presenter(s): Grohe et al.
Oral Presentation
Tumour Type(s): NSCLC
Presentation Number: 119O
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.

© 2019 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: March 2019